1 |
Yuan SM, Yan SL, Wu N. Unusual aspects of cardiac myxoma [J]. Anatol J Cardiol, 2017, 17(3): 241-247.
|
2 |
Ataie-Kachoie P, Pourgholami MH, Richardson DR, et al. Gene of the month: Interleukin 6 (IL-6) [J]. J Clin Pathol, 2014, 67(11): 932-937.
|
3 |
Song Z, Ren D, Xu X, et al. Molecular cross-talk of IL-6 in tumors and new progress in combined therapy [J]. Thorac Cancer, 2018, 9(6): 669-675.
|
4 |
Kolsuz M, Erginel S, Alataş O, et al. Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia [J]. Respiration. 2003, 70(6): 615-622.
|
5 |
de Brito RC, Lucena-Silva N, Torres LC. et al. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia [J]. BMC Pulmonary Medicine, 2016, 16(1): 170-180.
|
6 |
丁细霞,陈满君,潘玉先, 等. 420例成人流感样患者呼吸道病毒感染及其主要病原体分布 [J]. 现代预防医学, 2017, 44(20): 3781-3785.
|
7 |
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses [J]. Nat Rev Microbiol,2019, 17(3): 181-192.
|
8 |
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 [J]. N Engl J Med, 2020, 382(8): 727-733.
|
9 |
Li SW, Wang CY, Jou YJ, et al. SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6 [J]. Int J Mol Sci, 2016, 17(5):678.
|
10 |
Wang SF, Tseng SP, Yen CH, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins [J]. Biochem Biophys Res Commun, 2014, 451(2): 208-214.
|
11 |
Yoshikawa T, Hill T, Li K, et al. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells [J]. J Virol, 2009, 83(7): 3039-3048.
|
12 |
Li Y, Chen M, Cao H, et al. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response [J]. Microbes Infect, 2013, 15(2): 88-95.
|
13 |
Jones BM, Ma ES, Peiris JS, et al. Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids [J]. Clin Exp Immunol, 2004, 135(3): 467-473.
|
14 |
Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients [J]. J Med Virol, 2005, 75(2): 185-194.
|
15 |
Chien JY, Hsueh PR, Cheng WC, et al. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome [J]. Respirology, 2006, 11(6): 715-722.
|
16 |
Law HK, Cheung CY, Ng HY, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells [J]. Blood, 2005, 106(7): 2366-2374.
|
17 |
Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development [J]. J Immunol Res, 2019, 2019(1): 11-23.
|
18 |
Lau SKP, Lau CCY, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment [J]. J Gen Virol, 2013, 94(Pt 12): 2679-2690.
|
19 |
Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis [J]. J Infect Dis, 2014, 209(9): 1331-1342.
|
20 |
Al-Qahtani AA, Lyroni K, Aznaourova M, et al. Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ [J]. Oncotarget, 2017,8(6): 9053-9066.
|
21 |
Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option [J]. Lancet, 2020, 395(10224): e35-e36.
|
22 |
熊娟,江万里,周倩, 等. 新型冠状病毒肺炎89例临床特征、治疗及预后分析 [J].武汉大学学报(医学版), 2020: 1-5.
|
23 |
Wan SX, Yi QJ, Fan SB, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) [J/OL]. MedRxiv, 2020[2020-02-24].
|
24 |
Zhou YG, Fu BQ, Zheng XH, et al.Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus [J/OL]. Biorxiv,2020 [2020-02-24].
|
25 |
陈成,张小容,鞠振宇, 等. 新型冠状病毒肺炎引发细胞因子风暴的机制及相关免疫治疗研究进展 [J/OL] . 中华烧伤杂志, 2020, 36 (2020-03-02).
|
26 |
何黎黎,龚普阳,封玥, 等.中药在抗新型冠状病毒肺炎(COVID-19)引起的细胞因子风暴中的应用分析[J/OL].中草药, 1-11[2020-03-03].
|
27 |
闫坤龙,谢志萍,高寒春, 等. 2009—2011年南京地区儿童急性呼吸道感染人冠状病毒HKU1和NL63临床与流行病学特征 [J]. 中华实验和临床病毒学杂志, 2018, 32(6): 615-619.
|
28 |
Dominguez SR, Travanty EA, Qian Z, et al. Human coronavirus HKU1 infection of primary human type II alveolar epithelial cells: cytopathic effects and innate immune response [J]. PLoS One, 2013, 8(7): e70129.
|
29 |
Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells [J]. Respir Investig, 2020, 58(3): 155-168.
|
30 |
Tanaka T. IL-6 blockade therapy for inflammatory disease: current perspectives and future directions with Chinmeric Antigen Receptor T-Cells [J]. Nihon Rinsho Meneki Gakkai Kaishi, 2015, 38(6): 433-442.
|
31 |
Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) [J]. J Am Coll Cardiol, 2019, 74(25): 3099-3108512.
|
32 |
Hong SK, Kim HJ, Song CS, et al. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice [J]. Int Immunopharmacol, 2012, 13(1): 23-27.
|
33 |
Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus [J]. J Infect Public Health, 2016, 9(3): 227-230.
|
34 |
王琪,张坦,苏凤, 等.细胞因子释放综合征的不良反应研究现状 [J].中国临床药理学杂志, 2018, 34(7): 906-909.
|